PT  - JOURNAL ARTICLE
AU  - Suzuki, Yasuhito
AU  - Shibata, Yoko
AU  - Minemura, Hiroyuki
AU  - Nikaido, Takefumi
AU  - Tanino, Yoshinori
AU  - Fukuhara, Atsuro
AU  - Kanno, Ryuzo
AU  - Saito, Hiroyuki
AU  - Suzuki, Shuzo
AU  - Ishii, Taeko
AU  - Inokoshi, Yayoi
AU  - Sando, Eiichiro
AU  - Sakuma, Hirofumi
AU  - Kobayashi, Tatsuho
AU  - Kume, Hiroaki
AU  - Kamimoto, Masahiro
AU  - Aoki, Hideko
AU  - Takama, Akira
AU  - Kamiyama, Takamichi
AU  - Nakayama, Masaru
AU  - Saito, Kiyoshi
AU  - Tanigawa, Koichi
AU  - Sato, Masahiko
AU  - Kanbe, Toshiyuki
AU  - Kanzaki, Norio
AU  - Azuma, Teruhisa
AU  - Sakamoto, Keiji
AU  - Nakamura, Yuichi
AU  - Otani, Hiroshi
AU  - Waragai, Mitsuru
AU  - Maeda, Shinsaku
AU  - Ishida, Tokiya
AU  - Sugino, Keishi
AU  - Tsukada, Yasuhiko
AU  - Yamada, Ryuki
AU  - Sato, Riko
AU  - Omuna, Takumi
AU  - Tomita, Hikaru
AU  - Saito, Mikako
AU  - Watanabe, Natsumi
AU  - Rikimaru, Mami
AU  - Kawamata, Takaya
AU  - Umeda, Takashi
AU  - Morimoto, Julia
AU  - Togawa, Ryuichi
AU  - Sato, Yuki
AU  - Saito, Junpei
AU  - Kanazawa, Kenya
AU  - Iseki, Ken
TI  - Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
AID  - 10.1101/2021.12.19.21268078
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.19.21268078
4099  - http://medrxiv.org/content/early/2021/12/21/2021.12.19.21268078.short
4100  - http://medrxiv.org/content/early/2021/12/21/2021.12.19.21268078.full
AB  - Background Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan.Methods We enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635).Results The casirivimab-imdevimab users were older (P < 0.0001), had higher body temperature (≥ 38°C) (P < 0.0001) and greater rates of history of cigarette smoking (P = 0.0068), hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263–0.763; P = 0.0023). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021).Conclusion This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge.Summary This real-world retrospective study demonstrates the contribution of treatment with casirivimab-imdevimab to the prevention of deterioration in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) even during the Delta variant pandemic.Competing Interest StatementYoko Shibata and Hiroyuki Minemura received lecture fees and research grants from Chugai Pharmaceutical Co., Ltd. The other authors report no conflicts of interest related to this study.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The need for informed consent was waived because the study is retrospective. This study was approved by the Ethics Committee of Fukushima Medical University (approval number 2020-118, approved on August 3, 2020, updated September 01, 2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.BMIbody mass indexCIconfidence intervalCKDchronic kidney diseaseCOVID-19coronavirus disease 2019CRPC-reactive proteinECMOextracorporeal membrane oxygenationIQRinterquartile rangeLDHlactate dehydrogenaseORodds ratioPCRpolymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2